FAU has entered into a licensing agreement with Neuro Pharmalogics, Inc., a biopharmaceutical company focused on developing and commercializing innovative therapies for patients with rare neurological diseases.
FAU Harbor Branch study shows the relationship between changing sea ice and beluga whale migration and habitat patterns of several populations over two decades of dramatic sea ice changes in the Pacific Arctic.
FAU Harbor Branch scientists are researching ways to create a biosynthetic version of a compound found in a sea sponge that is very active against cancer cells.
FAU researchers and collaborators conducted a first-of-its-kind longitudinal study on twins to identify the degree to which siblings contribute to the increase in delinquent behavior and alcohol misuse.
A study on a plaque identifying toothpaste has shown significant reductions in dental plaque and inflammation throughout the body. These findings support the premise of reductions in heart attacks and strokes.
Sameer Hinduja, Ph.D., provides important tips to prevent children and young adults from being victimized. He is internationally renowned for his groundbreaking work on cyberbullying and safe social media use.
Two FAU Harbor Branch scientists, along with collaborators, are assessing the health and abundance of sharks and rays in the Indian River Lagoon.
Scientists from Sancilio & Company, Inc., a local biotech company, have joined forces with FAU's Center for Molecular Biology and Biotechnology to train a biopharmaceutical and drug development workforce.
Researchers from FAU, in collaboration with The Scripps Research Institute, have opened up the possibilities for rapid drug screens to treat seizures in the near future by using a microscopic nematode worm.
The National Science Foundation recently awarded a multi-year grant to a group of FAU Harbor Branch scientists to pursue work on an underwater holographic imaging system.